
Stanley Friedman
Examiner (ID: 12067)
| Most Active Art Unit | 1205 |
| Art Unit(s) | 1802, 1803, 2607, 1205 |
| Total Applications | 1808 |
| Issued Applications | 1509 |
| Pending Applications | 0 |
| Abandoned Applications | 299 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17266350
[patent_doc_number] => 11191754
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-07
[patent_title] => Inhibitors of nucleotidyl transferases and uses in herpes and hepatitis viral infections therefor
[patent_app_type] => utility
[patent_app_number] => 16/533204
[patent_app_country] => US
[patent_app_date] => 2019-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 19865
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16533204
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/533204 | Inhibitors of nucleotidyl transferases and uses in herpes and hepatitis viral infections therefor | Aug 5, 2019 | Issued |
Array
(
[id] => 17005475
[patent_doc_number] => 20210236636
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => PHARMACEUTICAL FORMULATIONS OF MASKED ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/262962
[patent_app_country] => US
[patent_app_date] => 2019-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16287
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17262962
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/262962 | PHARMACEUTICAL FORMULATIONS OF MASKED ANTIBODIES | Jul 29, 2019 | Abandoned |
Array
(
[id] => 15117017
[patent_doc_number] => 20190345141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => ARYL-SUBSTITUTED IMIDAZOLES
[patent_app_type] => utility
[patent_app_number] => 16/520277
[patent_app_country] => US
[patent_app_date] => 2019-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18526
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 201
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16520277
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/520277 | ARYL-SUBSTITUTED IMIDAZOLES | Jul 22, 2019 | Abandoned |
Array
(
[id] => 16450905
[patent_doc_number] => 20200360331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/517038
[patent_app_country] => US
[patent_app_date] => 2019-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46365
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16517038
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/517038 | COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES | Jul 18, 2019 | Abandoned |
Array
(
[id] => 16259924
[patent_doc_number] => 10751333
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2020-08-25
[patent_title] => Compositions and kits for omeprazole suspension
[patent_app_type] => utility
[patent_app_number] => 16/513604
[patent_app_country] => US
[patent_app_date] => 2019-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 32448
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16513604
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/513604 | Compositions and kits for omeprazole suspension | Jul 15, 2019 | Issued |
Array
(
[id] => 15038461
[patent_doc_number] => 20190330235
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/507523
[patent_app_country] => US
[patent_app_date] => 2019-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 469
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507523
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/507523 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | Jul 9, 2019 | Abandoned |
Array
(
[id] => 15038323
[patent_doc_number] => 20190330166
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => Proxisome Proliferator Activated Receptor (PPAR) Compounds and Methods of Using the Same
[patent_app_type] => utility
[patent_app_number] => 16/504815
[patent_app_country] => US
[patent_app_date] => 2019-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9433
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16504815
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/504815 | Proxisome proliferator activated receptor (PPAR) compounds and methods of using the same | Jul 7, 2019 | Issued |
Array
(
[id] => 17814263
[patent_doc_number] => 11419850
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
[patent_app_type] => utility
[patent_app_number] => 16/454862
[patent_app_country] => US
[patent_app_date] => 2019-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 7400
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16454862
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/454862 | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases | Jun 26, 2019 | Issued |
Array
(
[id] => 14893773
[patent_doc_number] => 20190290652
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES
[patent_app_type] => utility
[patent_app_number] => 16/440053
[patent_app_country] => US
[patent_app_date] => 2019-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2285
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16440053
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/440053 | METHOD FOR TREATMENT OF SOLID MALIGNANCIES INCLUDING ADVANCED OR METASTATIC SOLID MALIGNANCIES | Jun 12, 2019 | Abandoned |
Array
(
[id] => 15023349
[patent_doc_number] => 20190322679
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => ANTICANCER DRUG CANDIDATES
[patent_app_type] => utility
[patent_app_number] => 16/439300
[patent_app_country] => US
[patent_app_date] => 2019-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22138
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439300
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/439300 | ANTICANCER DRUG CANDIDATES | Jun 11, 2019 | Abandoned |
Array
(
[id] => 15209685
[patent_doc_number] => 20190367529
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => USE OF THE FL-ONE HUNDRED EIGHTEEN CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL-ONE HUNDRED EIGHTEEN DERIVATIVES FOR TREATMENT OF HUMAN DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/438025
[patent_app_country] => US
[patent_app_date] => 2019-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35472
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438025
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/438025 | Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease | Jun 10, 2019 | Issued |
Array
(
[id] => 14993689
[patent_doc_number] => 20190315802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/427691
[patent_app_country] => US
[patent_app_date] => 2019-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33938
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16427691
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/427691 | Therapeutically active compounds and their methods of use | May 30, 2019 | Issued |
Array
(
[id] => 15524639
[patent_doc_number] => 20200054625
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => Pharmaceutical Compositions
[patent_app_type] => utility
[patent_app_number] => 16/425401
[patent_app_country] => US
[patent_app_date] => 2019-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12945
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425401
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/425401 | Pharmaceutical Compositions | May 28, 2019 | Abandoned |
Array
(
[id] => 14833207
[patent_doc_number] => 20190275004
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/423216
[patent_app_country] => US
[patent_app_date] => 2019-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16423216
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/423216 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | May 27, 2019 | Abandoned |
Array
(
[id] => 15553199
[patent_doc_number] => 20200061011
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => METHODS OF TREATING HYPERCHOLESTEROLEMIA
[patent_app_type] => utility
[patent_app_number] => 16/423987
[patent_app_country] => US
[patent_app_date] => 2019-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11051
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16423987
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/423987 | METHODS OF TREATING HYPERCHOLESTEROLEMIA | May 27, 2019 | Abandoned |
Array
(
[id] => 14808223
[patent_doc_number] => 20190270721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-05
[patent_title] => NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT
[patent_app_type] => utility
[patent_app_number] => 16/419333
[patent_app_country] => US
[patent_app_date] => 2019-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48980
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16419333
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/419333 | Compounds and compositions for the inhibition of NAMPT | May 21, 2019 | Issued |
Array
(
[id] => 16977553
[patent_doc_number] => 20210221790
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME
[patent_app_type] => utility
[patent_app_number] => 17/055081
[patent_app_country] => US
[patent_app_date] => 2019-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23427
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055081
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/055081 | ABHD12 inhibitors and methods of making and using same | May 13, 2019 | Issued |
Array
(
[id] => 19043549
[patent_doc_number] => 11932633
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-19
[patent_title] => KRas G12C inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/053273
[patent_app_country] => US
[patent_app_date] => 2019-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22519
[patent_no_of_claims] => 41
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 338
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053273
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/053273 | KRas G12C inhibitors | May 5, 2019 | Issued |
Array
(
[id] => 17875492
[patent_doc_number] => 11447493
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Inhibitors of cyclin-dependent kinases
[patent_app_type] => utility
[patent_app_number] => 17/052162
[patent_app_country] => US
[patent_app_date] => 2019-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33597
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052162
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/052162 | Inhibitors of cyclin-dependent kinases | May 1, 2019 | Issued |
Array
(
[id] => 16839436
[patent_doc_number] => 20210147448
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => OXO-SUBSTITUTED COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/050747
[patent_app_country] => US
[patent_app_date] => 2019-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 125506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -90
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050747
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/050747 | Oxo-substituted compound | Apr 25, 2019 | Issued |